Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — FY2016 Earnings Presentation
75 slides from Daiichi Sankyo's earnings presentation, May 11, 2017
Slide 1: Top Management Presentation: Financial Results for FY2016
Top Management Presentation Financial Results for FY2016 (April 1, 2016 – March 31, 2017) DAIICHI SANKYO CO., LTD George Nakayama Sunao Manabe Chairman and CEO President and COO May 11, 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda FY2016 Financial Results FY2017 Consolidated Forecast Progress of 5-Year Business Plan 2
Slide 4: FY2016 Financial Results
FY2016 Financial Results 3
Slide 5: Overview of FY2016 Results
Overview of FY2016 Results (Bn JPY) FY2015 Results FY2016 Results YoY -3.2% Revenue 986.4 955.1 -31.3 Cost of Sales 318.6 349.4 +30.8 SG&A Expenses 328.8 302.5 -26.3 R&D Expenses 208.7 214.3 +5.7 -31.8% Operating Profit 130.4 88.9 -41.5 Profit before Tax 122.4 87.8 -34.6 -35.0% Profit attributable t
Slide 6: Impairment loss: Kitasato Daiichi Sankyo Vaccine (KDSV)
Impairment loss : Kitasato Daiichi Sankyo Vaccine (KDSV) Impairment test was needed by the delay of the progress for some pipeline projects centered on Measles-Mumps-Rubella vaccine According to impairment test, KDSV booked an impairment loss of 21.9 Bn JPY on tangible fixed assets and intangibl
Slide 7: Revenue
Revenue Decreased by 31.3 Bn JPY (Increased by 10.3 Bn JPY excl. forex impact) (Bn JPY) Japan FY2015 Results 986.4 Positive : Lixiana +12.0 Tenelia +7.6 Inavir +5.5 Efient +5.5 Japan Pralia +5.5 Memary +4.4 24.9 Nexium +1.6 (incl. Vaccines, OTC) Negative : Loxonin -10.7 Olmetec -4.4 Daiichi Sankyo,
Slide 8: Operating Profit
Operating Profit Decreased by 41.5 Bn JPY (Decreased by 16.1 Bn JPY excl. forex impact and special items) (Bn JPY) FY2015 Results 130.4 Revenue -31.3 incl. forex impact -41.6 Revenue 31.3 Cost of Sales +21.0 Increased in revenue excl. forex impact Impact of price revision in Japan Cost of Sales 21.0
Slide 9: Special Items
Special Items (Bn JPY) FY2015 Results FY2016 Results YoY Gain on sales of subsidiary -2.4 Gain on sales of fixed assets -1.1 Restructuring costs in SC 3.6 Cost of Sales +21.2 Impairment loss (Intangible) 1.9 Impairment loss (Vaccine) 20.6 Restructuring costs in SC 4.6 Restructuring costs in US 15.2
Slide 10: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 28.8 Bn JPY (Bn JPY) FY2015 Results 82.3 Operating Profit 41.5 Financial Income / Expenses -6.4 Improvement of forex gains/ losses Financial Income / Expenses 6.4 FY2015: Expenses relating to the sales of Sun Pharma shares etc. Income Taxes e
Slide 11: Income Taxes, Non-Controlling Interests
Income Taxes, Non-Controlling Interests (Bn JPY) KDSV* with Net Operating Loss FY2015 FY2016 from the previous term has been YoY Results Results not applicable to tax effect -28.3% accounting on its loss Profit before Tax 122.4 87.8 -34.6 The loss of KDSV was increased Income taxes etc. 42.0 40.3 -1
Slide 12: Revenue: Major Business Units
Revenue: Major Business Units (Bn JPY) FY2015 FY2016 vs. Forecast YoY Results Results (%) Japan 494.7 506.6 +11.9 100.3% Daiichi Sankyo Healthcare 53.4 66.7 +13.4 101.1% Daiichi Sankyo Inc. 185.1 142.3 -42.8 98.8% Olmesartan 111.6 66.4 -45.3 92.2% Welchol 48.4 45.5 -2.9 111.0% Effient 20.7 22.2 +1.5
Slide 13: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2015 FY2016 vs. Forecast YoY (%) Results Results Nexium ulcer treatment 82.4 84.0 +1.6 101.2% Olmetec antihypertensive agent 73.9 69.4 -4.4 100.6% Alzheimer’s disease Memary treatment 42.4 46.9 +4.4 95.6% Loxonin anti-inflammatory analgesic 48.1 37.4 -10.7
Slide 14: FY2017 Consolidated Forecast
FY2017 Consolidated Forecast 13
Slide 15: FY2017 Consolidated Forecast
FY2017 Consolidated Forecast (Bn JPY) FY2016 FY2017 YoY Results Forecast -2.6% Revenue 955.1 930.0 -25.1 Cost of Sales 349.4 340.0 -9.4 SG&A Expenses 302.5 300.0 -2.5 R&D Expenses 214.3 190.0 -24.3 +12.4% Operating Profit 88.9 100.0 +11.1 Profit before Tax 87.8 100.0 +12.2 +23.4% Profit attributable
Slide 16: FY2017 Consolidated Forecast (excl. special items)
FY2017 Consolidated Forecast (Bn JPY) FY2016 FY2017 Results YoY See next page Forecast (excl. special items) -2.6% Revenue 955.1 930.0 -25.1 Product mix (Impact of olmesartan 34.0% 36.6% LOE) Cost of Sales 325.2 340.0 +14.8 • Increase of co-promotion SG&A Expenses 290.8 300.0 +9.2 expenses (Japan・Ch
Slide 17: Revenue: Major Business Units
Revenue: Major Business Units (Bn JPY) FY2016 FY2017 YoY Results Forecast Japan 506.6 536.0 +29.4 Daiichi Sankyo Healthcare 66.7 69.0 +2.3 Daiichi Sankyo Inc. 142.3 62.0 -80.3 Luitpold 88.1 103.0 +14.9 Daiichi Sankyo Europe 71.0 66.0 -5.0 Asia, South and Central America (ASCA) 72.1 84.0 +11.9 16
Slide 18: Revenue: Global Products
Revenue: Global Products (Bn JPY) FY2016 FY2017 YoY Results Forecast Olmesartan 218.0 134.0 -84.0 Olmetec, Rezaltas (JPN) 87.0 63.0 -24.0 Benicar/Benicar HCT etc. (US) 66.4 14.0 -52.4 Olmetec/Olmetec Plus etc. (EU) 43.2 26.0 -17.2 Other subsidiaries, export, etc. 21.5 31.0 +9.5 Edoxaban 37.3 65.0 +2
Slide 19: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan 18
Slide 20: 2025 Vision: Global Pharma Innovator with Competitive Advantage in Oncology
2025 Vision Global Pharma Innovator with Competitive Advantage in Oncology Build a specialty area* centered on oncology as the core business Enrich regional value aligned with market needs Create innovative products – change SOC (Standard of Care) Realize shareholder value through highly eff
Slide 21: 5-Year Business Plan (FY2016 - FY2020)
5-Year Business Plan (FY2016 - FY2020) Challenge 1: Grow beyond FY2017 LOE Challenge 2: Establish Foundation of Sustainable Growth Revenue 1,100.0 Bn JPY Revenue 986.4 Bn JPY Revenue 940.0 Increase value of Bn JPY late-stage pipeline* OP *3 - 5 products launched within the next 5 years with peak-
Slide 22: Strategic Targets
Strategic Targets ~For establishing foundation of sustainable growth~ Six Strategic Targets Grow Edoxaban Grow as No.1 company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Cap
Slide 23: Grow Edoxaban
Dalichi-Sankyo Grow Edoxaban 22
Slide 24: Edoxaban
Edoxaban Over 120.0 Bn JPY (1 Bn USD) in FY2020 Expand launched and approved countries 65.0 Bn JPY Steady revenue growth in Japan, Germany and South Korea 37.3 Accelerate new evidence creation Bn JPY 15.0 Bn JPY FY2015 FY2016 FY2017 FY2020 Results Results Forecast Target 23 Conservative assump
Slide 25: Expand Launched and Approved Countries
Expand Launched and Approved Countries Launched and approved in over 20 countries Covered about 95% of DOAC* market potential Marketing alliance with JSC Servier in 15 countries (incl. Russia & CIS countries) in April 2017 Launched Approved Submitted As of April 2017 *DOAC : Direct Oral Anticoag
Slide 26: Growth in Japan
Growth in Japan (%) Market share reached third (18.2%) out of the four DOACs 50 40 30 Lixiana Product A 20 18.2% Product B Product C 10 0 Copyright © 2017 QuintilesIMS Calculated based on JPM 2014 Q1-2016 Q4 Reprinted with permission 25
Slide 27: Growth in Japan: Lixiana market share
0 5 10 15 20 25 30 35 (%) Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Source :Medi-trend Mar-15 Apr-15 May-15 Jun-15 Jul-15 Growth in Japan Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 new patients for AF+VTE Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Lixiana reached 32.0% of market share in
Slide 28: Growth in Germany and South Korea
Growth in Germany and South Korea Steady uptake of sales share after launch Germany South Korea 7.0% 6.5% 16.0% 14.0% 14.0% 6.0% 12.0% 5.0% 10.0% 4.0% 8.0% 3.0% 6.0% 2.0% 4.0% 1.0% 2.0% 0.0% 0.0% Aug-15 Sep-15 Aug-16 Sep-16 Aug-16 Sep-16 Feb-16 Feb-16 Jul-16 Jul-16 Oct-15 Oct-16 Oct-16 Jan-16 Apr-16
Slide 29: Maximize Product Value
Maximize Product Value Maximize product value by accelerating creation of new evidence Sustainable Growth (2021-) New Evidence (2015-2020) Maximize brand value Launch Strategy (2015-2017) Launch in major countries FY2015 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021- DOAC market Edoxaban 28
Slide 30: Accelerate New Evidence Creation
Accelerate New Evidence Creation Ongoing randomized controlled trials in various clinical settings Clinical Setting Primary Study Name (Comparator) Completion Study started since FY2016 Cardioversion Presented at (enoxaparin/ warfarin) ESC 2016 PCI (VKA) November 2018 Cardiac ablation (VKA) December
Slide 31: Accelerate New Evidence Creation: Registries
Accelerate New Evidence Creation Non-interventional studies and registries to generate real-world data with >100,000 patients including completed, ongoing and future research Study Name Clinical Setting Study started Edoxaban Treatment in routine since FY2016 clinical practice in AF Edoxaban Treatme
Slide 32: Grow as No.1 company in Japan
Grow as No.1 company in Japan 31
Slide 33: Grow Major Products in Japan
Grow Major Products in Japan Many of innovative major products reached No. 1 share and continue to expand market share 243.0 Bn JPY Share Share 227.0 No.1 No.1 Bn JPY Ulcer treatment Alzheimer’s 197.3 Nexium disease treatment Memary Bn JPY Share Share 171.1 No.1* No.1 Bn JPY Treatment for Treatment
Slide 34: Process for Sustainable Growth
Process for Sustainable Growth Realize sustainable growth by leveraging No.1 sales capabilities of leading company in Japan No.1 market share Continuous Growth of launch & sales Japan growth of own Business products No.1 evaluation Top class Sales growth sales capabilities Fine-tuned of acquired in
Slide 35: Achievements in FY2016
Achievements in FY2016 Launched anti epilepsy VIMPAT and filed an new indication Acquire 9 biosimilars in-licensed from Amgen valuable new products Expand strategic alliance in the diabetes field with Mitsubishi Tanabe Pharma Entered into a marketing alliance agreement for MT-2412, a combina
Slide 36: Growth of Sales Share
Growth of Sales Share Growth of Japan Business Japanese Pharmaceutical Companies (%) Share of Revenue (FY2012 - FY2016) 8.0 7.0 Daiichi 6.0 Sankyo 5.0 4.0 3.0 2.0 1.0 0.0 FY2012 FY2013 FY2014 FY2015 FY2016 Copyright © 2017 QuintilesIMS Calculated based on JPM Data 35 Reprinted with permission
Slide 37: "Opioid Switching" is now Available in Japan
“Opioid Switching” is now Available in Japan “Opioid switching”, a global standard way for use of opioids is now available in Japan with the approval of hydromorphone in Japan Hydromorphone Oxycodone Morphine Fentanyl Remifentanil Narurapid IR Manufacture and Sales Launch preparation Launched ー ー Ap
Slide 38: Expand US Businesses
Daiichi-Sankyo Expand US Businesses 37
Slide 39: Pain Franchise
Pain Franchise Movantik (Opioid-Induced Constipation: OIC) > 100 Bn JPY business Raise awareness of burden of OIC in FY2020 Licensed two abuse-deterrent opioids Plan to launch MorphaBond ER in 2017 CL-108 (Opioid-Induced Nausea & Vomiting: OINV) Received complete response letter from FDA
Slide 40: Luitpold Business
Luitpold Business Realize rapid and sustainable growth with Iron Franchise and Generic injectable franchise 1,250 Mn USD (150.0 Bn JPY) Iron Franchise Accelerate the growth of Injectafer by enhanced promotion by DSI 936 Mn USD (103.0 Bn JPY) 812 Mn USD 758 Mn USD (88.1 Bn JPY) (91.0 Bn JPY) 300
Slide 41: The U.S. IV Iron Market
The U.S. IV Iron Market Injectafer and Venofer keep over 70% market share in the U.S. IV iron market US IV Iron Market (includes dialysis) 800 762.2 700 658.4 30.9% 600 575.4 22.8% 11.4% 500 Mn USD Injectafer* 400 300 Venofer 200 58.5% 50.4% 44.2% 100 0 MAT Feb 2015 MAT Feb 2016 MAT Feb 2017 *Inject
Slide 42: New Sales Team for Injectafer
New Sales Team for Injectafer From Jan. 2017, LPI sales team for Injectafer has become DSI employees. With the LPI team, DSI formed a united sales team for Injectafer . Women’s Chronic IBD/ Heart ND-CKD Oncology Health GI Failure Cardiologist Gastro Nephrologist OBGYN Oncologist Infusion Center Pati
Slide 43: Injectafer: Investigating Additional Indications
Injectafer: Investigating Additional Indications Heart failure prevalence is 6.5 million in the U.S.* Iron deficiency is a common comorbidity that affects up to 50% (up to 3.25 million) of heart failure patients.**Approximately 10 million people are iron deficient in the U.S.*** Started in Mar. 2017
Slide 44: Generic Injectable Franchise
Generic Injectable Franchise The only way to deliver sustainable consistent growth is to continuously launch new products FY2016 Results 4 ANDA submissions, 1 ANDA approval FY2017 Targets 3 NDA submissions, 3 ANDA submissions 3 NDA submissions ANDA approval 3 ANDA submissions 4 ANDA submissions AN
Slide 45: Establish Oncology Business
Establish Oncology Business 44
Slide 46: Establish Oncology Business
Establish Oncology Business Daiichi Sankyo’s 2 Organization 2 New Cancer Franchises restructuring Antibody-Drug Established Conjugate(ADC) Biologics Unit Develop and expand Seamless technological transition DS’ proprietary technology Established Global Acute Myeloid Leukemia (AML) Oncology Marketing
Slide 47: Established Biologics Unit (Apr 2017)
Established Biologics Unit (Apr 2017) Develop manufacturing Optimize Develop Incubation Purification production method of modality* process process system biologics Seamless collaboration Establish seamless collaboration Accelerate development of biologics, such as DS-8201 Consolidate research and d
Slide 48: Established Global Oncology Marketing (Apr 2017)
Established Global Oncology Marketing (Apr 2017) Hired an experienced leader as Head of Global Oncology Marketing ⇒ Thierry Gruson, DVM, MBA Head of Global Oncology Marketing Global Oncology Global Brand Leaders New Product Quizartinib Planning & Portfolio DS-8201 27 yrs of oncology commercial e
Slide 49: ADC Franchise
ADC Franchise Preclinical stage Clinical stage DS-7300 DS-1062 U3-1402 DS-8201 (B7-H3 ADC) (TROP2 ADC) (HER3 ADC) (HER2 ADC) ADC franchise Additional ADCs DS-1001 DS-3032 Quizartinib (IDH1) (MDM2) (FLT3) AML franchise DS-3201 PLX-51107 (EZH1/2) (BRD4) 48
Slide 50: DS's Proprietary ADC technology
DS’s Proprietary ADC technology Proprietary Drug-Linker O O OH O N O O O O N H H H CysS N N N N N N O N H H H O O O O F Cysteine residue Drug-Linker O H O NH O N Conjugation chemistry F N O Cysteine linked, at sites of interchain disulfide bonds O H O Proprietary payload (DXd) Exatecan derivative Br
Slide 51: ADC technology: Mode of Action (MOA)
ADC technology: Mode of Action (MOA) ADC technology has broad application across multiple types of cancer Designed to deliver enhanced cancer cell destruction with less systemic exposure to chemotherapy Antigen Target cancer cell Endosome Bind to antigen Internalization Endolysosome Antibody Dru
Slide 52: ADC Franchise: DS pipeline
ADC Franchise: DS pipeline Antigen & General Cancer Types Own ADC Major Competitors Kadcyla: Roche (launched) Breast cancer DS-8201 HER2 SYD985: Synthon(Ph1) Gastric cancer Phase 1 MEDI4276: AZ(Ph1) Breast cancer U3-1402 MP-HER3-ADC: HER3 Lung cancer Phase 1 Mediapharma (pre-clinical) Breast cancer
Slide 53: Progress of ADC Franchise: DS-8201 HER2 ADC
Progress of ADC Franchise: DS-8201 HER2 ADC Progress of clinical trials FY2017 FY2018 FY2019 FY2020 HER2+ Breast Pivotal Phase 2 (JP/US) HER2+ Breast Ph1 (T-DM1 failure) Planed to start FY2017 H2 (T-DM1 failure) HER2+ Gastric Pivotal Phase 2 (JP) HER2+ Gastric Ph1 (Herceptin failure) Planed to sta
Slide 54: Progress of ADC Franchise: U3-1402 HER3 ADC
Progress of ADC Franchise: U3-1402 HER3 ADC Progress of phase 1 study HER3 positive refractory/metastatic breast cancer (Dec. 2016) TLR: FY2018 Q4 EGFRm NSCLC Expected to start from FY2017 Q3 Key reports at scientific conference AACR (Apr. 2017), poster presentation of pre-clinical res
Slide 55: U3-1402: Potential in EGFRm NSCLC
Progress of ADC Franchise: U3-1402 HER3 ADC Potential in EGFRm NSCLC HER3 expression after EGFR TKI EGFRm NSCLC patient journey treatment (in-vitro cell lines) 2nd line Gefitinib treatment (T790M-) 72h No approved 3nd line – + Fold Drug (T790M+) No approved 3.3 Drug MDA – 468 Tumor volume 1st line
Slide 56: U3-1402 anti-tumor activity in xenograft study
Progress of ADC Franchise: U3-1402 HER3 ADC U3-1402 was shown to have anti tumor activity on EGFR-TKI resistant NSCLC in xenograft study HER3 cell-surface protein level HCC827GR5 Xenograft study ▲ U3-1402 dosing 1. Upregulation of HER3 is observed in EGFR-TKI resistant NSCLC cell (HCC827GR5). 2. Ant
Slide 57: Other ADC Franchise: DS-1062 TROP2 ADC
Other ADC Franchise: DS-1062 TROP2 ADC TROP2 is highly expressing in a Pancreatic cancer variety of tumors (e.g., breast cancer, lung cancer, esophagus cancer) and TROP2-ADC effectively internalizes with binding antibody. Control Tumor volume DS-1062 is being investigated (mm3) against TROP2 exp
Slide 58: Other ADC Franchise: DS-7300 B7-H3 ADC
Other ADC Franchise: DS-7300 B7-H3 ADC B7-H3 is overexpressed at a high NSCLC frequency in wide range of solid B7-H3-ADC tumors, including esophageal, lung, endometrial, prostate cancer Control Tumor volume and also sarcoma, but low (mm3) expression in normal tissues. DS-7300 shows anti-tumor DS
Slide 59: AML Franchise
AML Franchise Preclinical stage Clinical stage DS-7300 DS-1062 U3-1402 DS-8201 (B7-H3 ADC) (TROP2 ADC) (HER3 ADC) (HER2 ADC) ADC franchise Additional ADCs DS-1001 DS-3032 Quizartinib (IDH1) (MDM2) (FLT3) AML franchise DS-3201 PLX-51107 (EZH1/2) (BRD4) 58
Slide 60: AML Franchise: Developing 3 of 7 Emerging Classes of Targets
AML Franchise: Developing 3 of 7 Emerging Classes of Targets Emerging classes of targets in AML 1. Growth factor receptor inhibition 4. Surface targets for immunotherapy Quizartinib (FLT3) 5. Activated signaling 6. Apoptosis 2. Transcriptional deregulation • DS-3201 (EZH1/2) • DS-1001 (IDH1) DS-3032
Slide 61: Progress of AML Franchise: Quizartinib FLT3 inhibitor
Progress of AML Franchise: Quizartinib FLT3 inhibitor Induction Consolidation Maintenance Relapsed / Refractory • Phase 3 study • Phase 3 study • Combination with SOC chemotherapy* • Monotherapy • First patient dosed Oct. 2016 • Overall Survival • Interim analysis was conducted by independent data m
Slide 62: Continuously Generate Innovative Medicine Changing SOC
Continuously Generate Innovative Medicine Changing SOC (Standard of Care) 61
Slide 63: Continuously Generate Innovative Medicine Changing SOC
Continuously Generate Innovative Medicine Changing SOC Primary Focused Area Oncology (incl. Immuno-Oncology) New Heart- Rare Horizon CNS Pain kidney disease Area disease disease Continuously Generate Innovative Medicine Changing SOC (Standard of Care) 62
Slide 64: Oncology: Partnership for Changing SOC
Oncology: Partnership for Changing SOC Implementing and partnering innovative technology for accelerating research and development Oncolytic virus Bi-specific antibody • G47Δ: DS-1647 Co-development with Dr. Todo, a • Cross-licensing and collaboration professor at the Institute of agreement with Zym
Slide 65: New Horizon Area: Partnership for Changing SOC
New Horizon Area: Partnership for Changing SOC Implementing and partnering innovative technology for accelerating research and development Pain CNS disease • Generate drugs for • Partnering with Heptares for neurodegenerative disease newly low-molecule drug through collaborative research with UCSF H
Slide 66: Enhance Profit Generation Capabilities
Enhance Profit Generation Capabilities 65
Slide 67: Enhance Profit Generation Capabilities
Enhance Profit Generation Capabilities Realize “Process Excellence”: Further cost reductions and streamlining <Enhancement of procurement: Target during 5YBP – 50.0 Bn JPY cost reductions for indirect materials*1> <5-Year FY2016 Actual: 13.2 Bn JPY cost reductions Business Plan> <Optimization in SC>
Slide 68: Enhance Cash Flow Generation Capabilities: Streamlining of Assets
Enhance Cash Flow Generation Capabilities: Streamlining of Assets Optimize capital expenditures To make an initial 15 Bn JPY investment to optimize and enhance its manufacturing capabilities to support its growing ADC pipeline, and optimize totally for pursuing the efficiency Reduce Cross-Shareh
Slide 69: Low Cost Funding & Efficient Operation for DS Group Cash Management
Low Cost Funding & Efficient Operation for DS Group Cash Management Low cost funding Issuance of unsecured straight bonds Under the environment of continuous low interest rates, became the first Japanese healthcare sector’s company to secure stable, low cost funds by issuing super-long-term bond
Slide 70: Shareholder Returns
Daiichi-Sankyo Shareholder Returns 69
Slide 71: Shareholder Returns
Shareholder Returns Shareholder Returns Policy during 5YBP* Total return ratio: 100% or more Annual ordinary dividend: more than 70 JPY Flexible acquisition of own shares * 5YBP: 5-year Business Plan (FY2016 - FY2020) FY2015 FY2016 FY2017 (Target Results Results Plan during 5YBP) Total return
Slide 72: Back-up
Back-up
Slide 73: FY2017 Major R&D Milestone Events
FY2017 Major R&D Milestone Events FY18-Q1 Project Indication/Study Q1 Q2 Q3 Q4 Denosumab Rheumatoid arthritis (JP) Under review CL-108 Pain/Opioid-induced nausea and vomiting (US) Re-submission CHS-0214 Rheumatoid arthritis (JP) submission (etanercept BS) Fibromyalgia Phase 3 study (US/EU) TLR Mirog
Slide 74: Major R&D Pipeline
Major R&D Pipeline As of May 2017 Therapeutic area Phase 1 Phase 2 Phase 3 Application DS-3032 (US/JP) DS-8273 (US) Patritumab (EU) Denosumab (JP) (MDM2 inhibitor) (Anti-DR5 antibody) (U3-1287 / Anti-HER3 antibody) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody) PLX7486 (US) DS-8
Slide 75: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp
Daiichi Sankyo Company — FY2016 Earnings Presentation on 6ix